CD4 and neoplasm: A previous study demonstrated a strong synergistic activation of HIV-1 production by clinically used HDACIs including VOR combined with the non-tumor-promoting NF-κB inducer prostratin in latently infected cell lines and resting CD4+ T cells isolated from cART-treated patients [72].